The frontline of drug discovery for the treatment of cancer

Download brochure

 
pipeline_q3_2_120

 Sentinel Oncology Pipeline 2009

 

 

Novel Drug Discovery for the Treatment of Cancer

Welcome to Sentinel Oncology. Our aim is to discover new chemical entities for the use in better treatments for cancer.

Learn about our research and development


Become a Product Partner

Sentinel Oncology is seeking partners to out-license products from its oncology pipeline at the pre-clinical development phase.

The Sentinel pipeline contains a number of novel small molecule programmes designed to inhibit key targets important in cancer therapy including angiogenesis & invasion, DNA repair pathways and tumour hypoxia.

The CHK1 programme is currently undergoing pre-clinical evaluation following successful in-vivo proof of concept studies.

Contact us to find out more

 

News

July 2009

Sentinel Oncology Limited FLT3 & FLT4 kinase inhibitor licensing opportunity

Sentinel Oncology, the Cambridge based cancer company focused on the discovery… read more

May 2009

Sentinel Oncology at BIO2009

Sentinel Oncology will be attending BIO Atlanta (18th-21st May 2009) and available for partnering discussions. Contact us… read more

February 2009

Sentinel Oncology Limited p70S6 kinase inhibitor licensing opportunity

Sentinel Oncology, the Cambridge based cancer company focused on the discovery of novel treatments for… read more